title: Molecular profiling indicates orthotopic xenograft of glioma cell lines simulate a subclass of human glioblastoma.
abstract: Cell line models have been widely used to investigate glioblastoma multiforme (GBM) pathobiology and in the development of targeted therapies. However, GBM tumours are molecularly heterogeneous and how cell lines can best model that diversity is unknown. In this report, we investigated gene expression profiles of three preclinical growth models of glioma cell lines, in vitro and in vivo as subcutaneous and intracerebral xenografts to examine which cell line model most resembles the clinical samples. Whole genome DNA microarrays were used to profile gene expression in a collection of 25 high-grade glioblastomas, and comparisons were made to profiles of cell lines under three different growth models. Hierarchical clustering revealed three molecular subtypes of the glioblastoma patient samples. Supervised learning algorithm, trained on glioma subtypes predicted the intracerebral cell line model with one glioma subtype (r = 0.68; 95% bootstrap CI -0.41, 0.46). Survival analysis of enriched gene sets (P < 0.05) revealed 19 biological categories (146 genes) belonging to neuronal, signal transduction, apoptosis- and glutamate-mediated neurotransmitter activation signals that are associated with poor prognosis in this glioma subclass. We validated the expression profiles of these gene categories in an independent cohort of patients from 'The Cancer Genome Atlas' project (r = 0.62, 95% bootstrap CI: -0.42, 0.43). We then used these data to select and inhibit a novel target (glutamate receptor) and showed that LY341595, a glutamate receptor specific antagonist, could prolong survival in intracerebral tumour-implanted mice in combination with irradiation, providing an in vivo cell line system of preclinical studies.
authors: Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors: Uma T
authors: UT
authors: Shankavaram
authors: Markus
authors: M
authors: Bredel
authors: William E
authors: WE
authors: Burgan
authors: Donna
authors: D
authors: Carter
authors: Philip
authors: P
authors: Tofilon
authors: Kevin
authors: K
authors: Camphausen
references: Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8287-92
references: 15928080
references: Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9
references: 15827123
references: Cancer Res. 2005 May 15;65(10):4088-96
references: 15899798
references: J Neurochem. 2003 Mar;84(6):1288-95
references: 12614329
references: Clin Cancer Res. 1997 Apr;3(4):523-30
references: 9815715
references: Nature. 2008 Oct 23;455(7216):1061-8
references: 18772890
references: N Engl J Med. 2009 Feb 19;360(8):765-73
references: 19228619
references: Cancer Res. 2009 Mar 1;69(5):2091-9
references: 19244127
references: J Cereb Blood Flow Metab. 2001 Sep;21(9):1013-33
references: 11524608
references: Br J Cancer. 2011 Feb 15;104(4):545-53
references: 21119666
references: Cancer Res. 2005 Oct 1;65(19):8679-89
references: 16204036
references: Oncogene. 2003 Apr 17;22(15):2361-73
references: 12700671
references: Cancer Res. 2004 Sep 15;64(18):6503-10
references: 15374961
references: Cancer Cell. 2010 Jan 19;17(1):98-110
references: 20129251
references: Cancer Res. 2004 Oct 1;64(19):6892-9
references: 15466178
references: Clin Cancer Res. 2009 May 1;15(9):3050-7
references: 19366835
references: Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72
references: 12011421
references: Cancer Res. 1988 Feb 1;48(3):589-601
references: 3335022
references: Cancer Biol Ther. 2005 Jul;4(7):759-62
references: 15970688
references: Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):251-66
references: 12118559
references: Cancer Cell. 2006 Mar;9(3):157-73
references: 16530701
references: Neuro Oncol. 2005 Jul;7(3):236-45
references: 16053698